Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.45 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.45 |
| ▸ | IKZF1 | Q13422 | 4/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26608659 | 0.93 | CRBN (0.41) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL26608692 | 0.93 | IKZF2 (0.46) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL26610450 | 0.92 | IKZF2 (0.45) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL26608702 | 0.92 | IKZF2 (0.44) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL23703681 | 0.91 | CRBN (0.43) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL26609959 | 0.90 | IKZF2 (0.44) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL21634441 | 0.86 | IKZF2 (0.51) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL22345825 | 0.86 | IKZF2 (0.61) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL31025903 | 0.86 | IKZF2 (0.61) | CRBNDDB1IKZF2IKZF1IKZF3 | |
| SCHEMBL19585928 | 0.86 | CRBN (0.57) | CRBNDDB1IKZF2IKZF1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11236103-B2 | Bifunctional compounds | BIOTHERYX, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2021155050-A1 | KINASE MODULATORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | CRBN 245/4885DDB1 1516/4885IKZF2 2777/4885 |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | CRBN 1405/4885DDB1 103/4885IKZF2 1128/4885 |
| US-11236103-B2 | Bifunctional compounds | CDK2, CDK6, CDK5 | CRBN 1405/4885DDB1 103/4885IKZF2 1128/4885 |
| US-20230002371-A1 | RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KRAS, RSU1, RAB1A | CRBN 407/4885DDB1 1783/4885IKZF2 2454/4885 |
| US-20220153751-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | CRBN 1405/4885DDB1 103/4885IKZF2 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.